Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $90.4444.

Several research firms have recently issued reports on MNPR. Lake Street Capital initiated coverage on Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Raymond James Financial began coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 target price for the company. Chardan Capital boosted their price target on shares of Monopar Therapeutics from $60.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Oppenheimer set a $115.00 price target on shares of Monopar Therapeutics and gave the stock an “outperform” rating in a research note on Thursday.

Insider Transactions at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares of the company’s stock, valued at $17,303,573.86. This represents a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kim R. Tsuchimoto sold 8,904 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the transaction, the director owned 11,486 shares in the company, valued at approximately $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 592,733 shares of company stock valued at $36,700,227 in the last quarter. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey purchased a new position in Monopar Therapeutics in the 2nd quarter worth about $34,000. AlphaQuest LLC acquired a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $44,000. JPMorgan Chase & Co. raised its holdings in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Monopar Therapeutics in the 2nd quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics in the 2nd quarter worth approximately $104,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $99.39 on Wednesday. The firm has a market capitalization of $613.24 million, a P/E ratio of -29.85 and a beta of 1.42. Monopar Therapeutics has a 12-month low of $4.50 and a 12-month high of $101.06. The business has a 50 day simple moving average of $48.63 and a 200 day simple moving average of $41.29.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. Research analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.